Spots Global Cancer Trial Database for STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)

Official Title: STEREOtactic Radiation and Adjuvant Chemotherapy in Lung Cancer (STEREO)

Study ID: NCT01300299

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

Stereotactic Body Radiation Therapy

Study Description

Brief Summary: This trial will test the feasibility of adjuvant chemotherapy after stereotactic body radiation therapy for early stage non-small cell lung cancer (NSCLC).

Detailed Description: This study evaluates the effect of adjuvant chemotherapy in patients who received treatment with stereotactic radiation for early stage lung cancer and who are at high risk for microscopic metastatic disease. Chemotherapy in the form of cisplatin/docetaxel or cisplatin/pemetrexed will be administered approximately six weeks after Stereotactic Body Radiation Therapy (SBRT). Patients will then undergo follow up clinical evaluation and imaging to evaluate treatment response and for surveillance. A patient population of 65 patients will be required. Enrollment in this protocol is planned by multi center involvement in the state of Kentucky as part of the Kentucky Trial Network (KTN).